alexa Revisiting the Current Assays Associated to Host Immune Responses Against Tuberculosis Infection | OMICS International
ISSN: 2329-8731
Journal of Infectious Diseases & Preventive Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Revisiting the Current Assays Associated to Host Immune Responses Against Tuberculosis Infection

Bianca Mothé1 and Paulo RZ. Antas2*

1Department of Biology, California State University San Marcos, San Marcos, CA, USA, 92096

2Laboratório de Imunologia Clínica, Instituto Oswaldo Cruz, FIOCRUZ,, Rio de Janeiro, RJ, Brazil

*Corresponding Author:
Paulo RZ. Antas
Laboratório de Imunologia Clínica
Instituto Oswaldo Cruz, Rio deJaneiro, Brazil
Tel: +55-21-3865-8152
E-mail: [email protected]

Received Date: February 12, 2015 Accepted Date: April 23, 2015 Published Date: May 05, 2015

Citation: Mothé B, Antas PRZ (2015) Revisiting the Current Assays associated to Host Immune Responses against Tuberculosis Infection. J Anc Dis Prev Rem 3:123. doi: 10.4172/2329-8731.1000123

Copyright: © 2015 Mothé B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Infectious Diseases & Preventive Medicine

Mini Review

As an ancient microbe, Mycobacterium tuberculosis (MTB) is an extremely successful pathogen. MTB causes more deaths worldwide now than at any previous time in history as the World Health Organization (WHO) estimates that approximately one-third of the world’s population (roughly 2 billion total) is infected with MTB [1]. MTB is a major health threat, causing 9 million new infections and between 2 and 3 million deaths annually. Future prospects look bleak due to the increasing impact of HIV and drug resistance MTB strains (MDR) on the TB epidemic [1].

The clinical course of TB provides clues as to the mechanisms that underlie MTB’s success as a pathogen. First, MTB establishes infection with a small inoculum, suggesting that it inhibits innate immune responses. Second, it often persists throughout the life of the host, suggesting evasion of adaptive immunity. Third, the transmission of MTB from one host to another typically depends upon the formation of lung cavities in which aerosols are generated by coughing or sneezing. The mechanisms of lung cavitation are complex but include bystander damage of healthy tissue by the host cellular immune response. It is generally thought that granuloma formation is a means by which the host controls certain pathogens, most notably mycobacteria and fungal species [2]. Granulomas form in animal models of TB and in human infection the scarred result of the granulomatous response to initial infection is sometimes observed as a calcified lesion abutting the pleural in a lower lobe of the lung, the “Ghon lesion” [3]. Although the granuloma limits the extent of early infection, it is ultimately cell-mediated immunity involving T-cells that control MTB replication.

Protective host immune responses involve T-cells and macrophages (Mø), whereas antibodies are unimportant by comparison [4]. MHC class I pathways and CD8+ T-cells appear to be important in the host containment of virulent MTB [5-7]. Previous studies demonstrated that CD8+ T-cell lines were capable of inhibiting MTB growth in vitro [8]. CD8+ T-cells function as cytotoxic effector cells and it has been suggested that these cells play the greatest role in lysing infected cells in lesion that still contain few bacteria and therefore sterilize the granuloma [9,10]. It has been shown that in mice, moderate levels of protection can be obtained upon transferring CD8+ T-cells even at late stages of infection [9,11]. In contrast, in most cases, the protection afforded by the CD4+ T-cells is much greater than that seen by CD8+ T-cells [12]. CD4+ T-cells, mediated by MHC class II pathways, secrete IFN-γ and activate Mø to produce reactive oxygen species (ROS) and nitric intermediates (RNI), thereby enhancing their microbicidal activity. In mice, depletion of CD4+ T-cells prior to infection leads to increased bacterial burden and shortened survival [12-15]. These results are also shown in knockout models as both CD4–/– and MHC-II–/– mice are extremely susceptible to MTB infection [16]. One of the difficulties in discerning the nature of the T-cell responses that correlate with protection has been that the rodent models used to study TB do not naturally “contain” infection in a manner analogous to how humans “contain” infection. Clinical observations and studies in humans provide insight into the components of true “containment.”

The development of safe and effective vaccines for both drug-sensitive MTB and MDR remains a high priority for the scientific community. For decades, a number of factors have been considered responsible for the variable efficacy of M. bovis BCG vaccine, the only vaccine still available against TB. These factors are related to the strain, the dose, and protocol for administer the vaccine [17]. Ideally, a vaccine to prevent TB would confer lifelong protection. Despite significant efforts over the course of several decades, several important issues related to the immune responses or epitopes recognized by MTB remain to be addressed. An NIH-sponsored workshop of leading scientists and experts held in June 2007 reviewed data on T-cell and B-cell epitopes derived from MTB, and identified several important knowledge gaps:

• Epitopes have been described for only a small fraction of the MTB genome

• more systematic data is necessary, addressing the recognition of different antigens and epitopes in different stages of MTB infection and disease, and in different ethnicities

• definition of epitopes recognized in small animals and non-human primates would also be beneficial to further evaluations of new vaccine candidates and vaccination strategies.

CD4+ T-cell populations appear to be very important as HIV-infected persons with latent TB infection are at high risk of progressing to active TB, and frequently present with extrapulmonary or disseminated infection [18,19]. Furthermore, treatment of HIV-TB co-infected persons with antiretroviral therapy often causes increased clinical and radiographic evidence of TB in the lungs as the CD4+ count recovers – the so-called “paradoxical reaction”, or “immune-reconstitution inflammatory syndrome-IRIS” [18,20]. In summary, both HIV and TB are life-threatening pathogens in their own right, but their synergic effects on the immune system during co-infection markedly enhance their effect on the host [20-22].

In terms of assays to detect cellular immune responses in the context of TB, there are few that are clinically available. One of the main issues that exist is what specific antigens from MTB are eliciting immune responses. The tuberculin skin test (TST) does not measure antigen-specific CD4+ or CD8+ T-cells and often gives false results [23]. The IFN-gamma release assays-IGRA, such as Quantiferon-Gold (QFT) and T-SPOT.TB, however, are more appropriate in detecting TB-specific responses [24]. The three antigens composing the QFT test, ESAT-6, CFP-10, and TB7.7, are represented as peptides and detected using whole blood [25]. Nevertheless, there are now more specific assays to detect immune responses after infection with MTB.

In all of these assays, a clear understanding of which antigens from MTB elicit immune responses is direly needed. Recent studies have focused on the identification of new antigens [26-31]. These studies have varied from in silico approaches, [31] to gene expression approaches [29] as well as MHC-specific methods [26,27,30]. The identification of TB-specific antigens that elicit immune responses provides the framework for new assays to assess cellular immunogenicity.

New assays to detect CD4+ and CD8+ T-cell responses after MTB infection includes cell specific detection systems, such as flow cytometry and enzyme based assays (such as ELISPOT) [24,32-37]. These assays will quantitatively and qualitatively measure specific CD4+ and/or CD8+ T-cell responses that are specific for MTB. However, albeit TB is the leading cause of death in AIDS patients worldwide, very little is known about early TB infection or MTB/HIV co-infection in infants. Thus, clinically relevant newborn animal model to study TB infection is urgently needed. An aerosol model in neonatal nonhuman primates which mimics clinical and bacteriological characteristics of MTB infection, with the potential to allow the establishment of a TB co-infection model of pediatric AIDS, as seen in human newborns/infants has been established [38]. There, post infection specific cell-mediated immune responses and lesions were detected suggestive of the classic Ghon focus in human children, as it represents the first example of early MTB infection of newborn macaques. Using ELISPOT assays, the IL-12 production correlated with early MTB infection lesions seen by routine thoracic radiographs. That study indicates a unique opportunity to further characterize immunopathogenesis and establish a MTB/SIV co-infection model for pediatric AIDS.

In sum, MTB is an extremely well adapted pathogen which has co-existed with the human host for millennia, and it has learned how to modulate potentially protective host immune responses to insure its own survival. Although there is still no correlate for protection in TB, there might be a harmonization of laboratory assays which ideally can be used to evaluate the immunogenicity, safety and parameters, such as vaccine "take" of a TB vaccine candidate. Better understanding of the human immune response to MTB infection and disease, plus the recent progress in immunology, microbiology, and molecular genetics, will provide fundamental shifts that promise to have extraordinary impact on the approaches to TB control. Ultimately, it is hoped that progress in the field of vaccinology will lead to a more rational approach towards the improvement of the BCG vaccine.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 11983
  • [From(publication date):
    December-2015 - Apr 23, 2018]
  • Breakdown by view type
  • HTML page views : 8162
  • PDF downloads : 3821

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version